CD14 and hepatocellular carcinoma: However, neither NF-κB inhibitor JSH-23 nor STAT3 inhibitor BBI608 could reverse HCC exosome-induced upregulation of PD-L1 and CD14 on neutrophils (Figure S10A-B).